Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A

1(33.3%)

Phase 2

1(33.3%)

Phase 1

1(33.3%)

3Total

N/A(1)

Phase 2(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT07351565Phase 1Not Yet Recruiting

Chemotherapy Plus Pitavastatin Guided by Patient-Derived Tumor-like Cell Clusters in Refractory Non-Small Cell Lung Cancer

Role: lead

NCT07243964Recruiting

Multi-Omics-Based Prediction of Allograft Dysfunction After Lung Transplantation

Role: lead

NCT07139041Phase 2Not Yet Recruiting

Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III NSCLC

Role: lead

NCT05542992Unknown

Deep Learning Model for Pure Solid Nodules Classification

Role: lead

NCT02952261Not ApplicableCompleted

Application of 3D Printing Technique in Small Pulmonary Nodule Localization

Role: lead

All 5 trials loaded